33159-27-2

Usage

InChI:InChI=1/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1

Upstream product

• 1740-19-8 dehydroabietic acid 
• 514-10-3 abietic acid 

Downstream Products

• 86408-71-1 12-sulfodehydroabietic acid disodium salt 
• 1740-19-8 dehydroabietic acid 

Relevant academic research and scientific papers

Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation

A series of dehydroabietic acid (DHAA) dipeptide derivatives containing the sulfonamide moiety were designed, synthesized and evaluated for inhibition of MMPs as well as the effects of in vitro cell migration. These compounds exhibited relatively good inhibition activity against MMPs with IC50 values in low micromolar range. A docking study of the most active compound 8k revealed key interactions between 8k and MMP-3 in which the sulfonamide moiety and the dipeptide group were important for improving activity. It is noteworthy that further antitumor activity screening revealed that some compounds exhibited better inhibitory activity than the commercial anticancer drug 5-FU. In particular, compound 8k appeared to be the most potent compound against the HepG2 cell line, at least partly, by inhibition of the activity of MMP-3 and apoptosis induction. The treatment of HepG2 cells with compound 8k resulted in inhibition of in vitro cell migration through wound healing assay and G1 phase of cell cycle arrested. In addition, 8k-induced apoptosis was significantly facilitated in HepG2 cells. Thus, we conclude that DHAA dipeptide derivatives containing the sulfonamide moiety may be the potential MMPs inhibitors with the ability to suppress cells migration.

One method for preparing card time of special sodium

The invention discloses a method for preparing ecabet sodium. The method disclosed by the invention is characterized by comprising the following steps of carrying out sulfonation reaction on dehydroabietic acid (formula III) as a starting material and fuming sulfuric acid to obtain 12-sulfonic dehydroabietic acid (formula II) and enabling the compound shown as the formula II and a sodium-forming agent to form a sodium salt in a solvent system at least containing water to obtain ecabet sodium. By virtue of the method disclosed by the invention, the deficiencies of the prior art are overcome and the method has the advantage of high sulfonation yield and high selectivity in sodium salt forming, simple operation, safety and environment friendliness and is suitable for industrial production.

Sulphonated dehydrogenated sylvate, the preparation and use

This invention relates to salts of sulfodehydroabietic acid with bismuth or zinc, a kind of new salt useful in treating digestive canal ulcer, acute and chronic gastritis, and erosive gastritis etc., as well as its preparation and use. Said salts can be represented by formula (1), wherein R is Bi(OH)++ or Zn++, 2Bio+, 1/2ZnH, n=0-10. The preparation method comprises following steps: (a) sequentially treating the industrial abietic acid calcium salt with acid, base and extracting with organic solvent to give abietic acid with less isomer; (b) reacting said abietic acid with Pd/C to provide dehydroabietic acid, then converting it to pure sulphonic product, namely sulfodehydroabietic acid, via sulphonation and recrystallization; (c) by use of neutralization or salt displacement reaction to convert the sulphonic product of zinc or bismuth salts of sulfodehydroabietic acid. The resultant salts can used to prepare medicine for treating digestive canal ulcer and gastritis.